Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
Status:
Not yet recruiting
Trial end date:
2026-08-26
Target enrollment:
Participant gender:
Summary
This phase II clinical trial evaluates the effectiveness of palbociclib and binimetinib in
treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class
of medications called kinase inhibitors. They work by blocking the action of abnormal
proteins that signals cancer cells to multiply. This trial may help researchers understand if
giving the combination of palbociclib and binimetinib can help improve the amount of time
before the cancer grows in patients with patients with low grade serous ovarian cancer who
have certain changes in the tumor DNA. This trial may also help researchers understand if
giving the combination of palbociclib and binimetinib can help improve outcomes among
patients with low grade serous ovarian cancer who have previously received a MEK inhibitor.
For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and
low grade serous ovarian cancers, this trial may help researchers understand if giving the
combination of palbociclib and binimetinib can improve the clinical outcome of survival
without progression in patients who have certain changes in their tumor's DNA.